Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding
- Author(s)
- Kuzich, JA; Heynemann, S; Geoghegan, N; Evelyn, C; O'Mahoney, S; Wilson, S; Campbell, J; Rogers, K; Solomon, B; Westerman, D; Pasricha, SR;
- Journal Title
- Pathology
- Publication Type
- epub ahead of print
- Abstract
- We reviewed haematological investigations for 43 patients treated at a single centre with alectinib, an inhibitor of anaplastic lymphoma kinase (ALK) which is considered standard first-line treatment for patients with ALK-rearranged advanced non-small cell lung cancer. Ninety-five percent of patients developed marked acanthocytosis, echinocytosis and/or spheroacanthocytosis, not observable with prior treatment with other ALK-inhibitors. Anaemia developed in 73% of patients (38% <100 g/L, 8% <80 g/L), though definite new haemolysis was present in only 11%. Eosin-5-maleimide binding was reduced in all assessed patients, and increased membrane cholesterol was identified in one patient assessed with lattice light sheet microscopy. We have identified a previously undescribed phenomenon whereby alectinib induces red cell membrane abnormalities in nearly all patients through an unclear, but likely ALK-independent, mechanism, resulting in mild anaemia without universal haemolysis.
- Publisher
- Elsevier
- Keywords
- Alectinib; acanthocytosis; eosin-5-maleimide; spherocytosis
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 33618863
- Publisher's Version
- https://doi.org/10.1016/j.pathol.2020.10.023
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-03-09 01:36:52
Last Modified: 2021-03-09 02:18:37